Immutep Limited
Immutep Limited (IMM.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Immutep Limited (IMM.AX), covering cash flow, earnings, and balance sheets.
Immutep Limited (IMM.AX) Income Statement & Financial Overview
Explore comprehensive income reports for Immutep Limited IMM.AX, broken down by year and quarter.
Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2022 |
---|---|---|---|---|
Revenue | $3.15M | $1.73M | $2.11M | $1.82M |
Cost of Revenue | $25.33M | $21.11M | $20.44M | $924019.00 |
Gross Profit | -$22.18M | -$19.38M | -$18.33M | $896169.00 |
Gross Profit Ratio | -$7.05 | -$11.20 | -$8.68 | $0.49 |
R&D Expenses | $25.33M | $21.11M | $20.44M | $9.82M |
SG&A Expenses | $4.23M | $4.05M | $4.80M | $20.91M |
Operating Expenses | $29.56M | $25.16M | $25.24M | $20.91M |
Total Costs & Expenses | $54.90M | $46.27M | $45.67M | $21.83M |
Interest Income | $3.14M | $1.88M | $2.00M | $635310.00 |
Interest Expense | $0.00 | $0.00 | $0.00 | $5414.00 |
Depreciation & Amortization | $23477.00 | $1.08M | $929607.00 | $924019.00 |
EBITDA | -$26.39M | -$22.35M | -$22.20M | -$20.91M |
EBITDA Ratio | -$8.38 | -$12.91 | -$10.52 | -$11.49 |
Operating Income | -$51.75M | -$44.54M | -$43.56M | -$21.83M |
Operating Income Ratio | -$16.44 | -$25.73 | -$20.64 | -$11.99 |
Other Income/Expenses (Net) | $29.37M | $23.05M | $22.34M | $2.56M |
Income Before Tax | -$22.38M | -$21.49M | -$21.23M | -$19.27M |
Income Before Tax Ratio | -$7.11 | -$12.41 | -$10.06 | -$10.59 |
Income Tax Expense | $0.00 | $0.00 | $0.00 | $1.00 |
Net Income | -$22.38M | -$21.49M | -$21.23M | -$19.27M |
Net Income Ratio | -$7.11 | -$12.41 | -$10.06 | -$10.59 |
EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
Diluted EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
Weighted Avg Shares Outstanding | $1.45B | $1.21B | $1.19B | $873.28M |
Weighted Avg Shares Outstanding (Diluted) | $1.45B | $1.22B | $1.19B | $913.12M |
Over the last four quarters, Immutep Limited achieved steady financial progress, growing revenue from $1.82M in Q4 2022 to $3.15M in Q2 2025. Gross profit stayed firm with margins at -705% in Q2 2025 versus 49% in Q4 2022. Operating income totaled -$51.75M in Q2 2025, maintaining a -1644% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$26.39M. Net income dropped to -$22.38M, with EPS at -$0.02. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan